Tomoko Fujita

3PUBLICATIONS
24CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Nov 07, 2022
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study.

Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama

|Oct 21, 2022
Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.

Tomohiro Nishina, Tomoko Fujita, Naoto Yoshizuka

|Aug 11, 2021
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.

Keiichi Fujiwara, Hiroyuki Fujiwara, Hiroyuki Yoshida

Pageof 1

Frequent Collaborators

2 joint publications

Kosho Murayama

2 joint publications

Ko Sugibayashi

1 joint publications

Keiichi Fujiwara

1 joint publications

Hiroyuki Fujiwara